Literature DB >> 35470421

Blood biomarkers for Alzheimer's disease and related disorders.

Henrik Zetterberg1,2,3,4,5, Jonathan M Schott4,6.   

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disease and the single commonest cause of dementia. Many other diseases can, however, cause dementia, and differential diagnosis can be challenging, especially in early disease stages. For most neurodegenerative dementias, accumulation of brain pathologies starts many years before clinical onset; the ability to detect these pathologies paves the way for targeted disease-modifying prevention trials. AD is associated with β-amyloid and tau pathologies, which can be quantified using cerebrospinal fluid and imaging biomarkers and, more recently, using highly sensitive blood tests. While for the most part, specific biomarkers of non-AD neurodegenerative dementias are lacking, non-specific biomarkers of neurodegeneration are available. This review summarizes recent advances in the neurodegenerative dementia blood biomarker research and discusses the next steps required for clinical implementation.
© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Alzheimer's disease; biomarker; blood biomarkers; dementia; neurofilament light; plasma; tau amyloid

Mesh:

Substances:

Year:  2022        PMID: 35470421     DOI: 10.1111/ane.13628

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  4 in total

1.  SARS-CoV-2 Neuroinvasion, Inflammatory Neurodegeneration and Alzheimer's Disease.

Authors:  Yuhai Zhao; Walter J Lukiw
Journal:  Front Cell Neurosci       Date:  2022-06-17       Impact factor: 6.147

Review 2.  Taurine and Astrocytes: A Homeostatic and Neuroprotective Relationship.

Authors:  Sofía Ramírez-Guerrero; Santiago Guardo-Maya; Germán J Medina-Rincón; Eduardo E Orrego-González; Ricardo Cabezas-Pérez; Rodrigo E González-Reyes
Journal:  Front Mol Neurosci       Date:  2022-07-05       Impact factor: 6.261

3.  SARS-CoV-2, long COVID, prion disease and neurodegeneration.

Authors:  Yuhai Zhao; Vivian R Jaber; Walter J Lukiw
Journal:  Front Neurosci       Date:  2022-09-27       Impact factor: 5.152

4.  Alzheimer's disease: insights from a network medicine perspective.

Authors:  Federica Conte; Paola Paci
Journal:  Sci Rep       Date:  2022-10-07       Impact factor: 4.996

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.